EYDENZELT (Celltrion Healthcare Australia Pty Ltd)
Product name
EYDENZELT
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
Aflibercept
Registration type
EOI
Indication
EYDENZELT 2 mg (aflibercept) is indicated in adults for the treatment of:
- neovascular (wet) age-related macular degeneration (wet AMD)
- visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO)
- visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO)
- diabetic macular oedema (DME)